ID   TC-32
AC   CVCL_7151
SY   TC32
DR   BTO; BTO:0004227
DR   BioGRID_ORCS_Cell_line; 199
DR   cancercelllines; CVCL_7151
DR   Cell_Model_Passport; SIDM01465
DR   ChEMBL-Cells; CHEMBL4295485
DR   ChEMBL-Targets; CHEMBL4296499
DR   Cosmic; 759891
DR   Cosmic; 1078387
DR   Cosmic; 1084513
DR   Cosmic; 1718432
DR   Cosmic; 2060803
DR   Cosmic; 2228244
DR   Cosmic; 2294588
DR   DepMap; ACH-001205
DR   GEO; GSM1676322
DR   GEO; GSM1701655
DR   GEO; GSM1899423
DR   PharmacoDB; TC32_1566_2019
DR   Progenetix; CVCL_7151
DR   PubChem_Cell_line; CVCL_7151
DR   Wikidata; Q54971813
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RX   DOI=10.5282/edoc.27750;
RX   PubMed=3004699;
RX   PubMed=3390826;
RX   PubMed=8040301;
RX   PubMed=16631476;
RX   PubMed=22142829;
RX   PubMed=24312454;
RX   PubMed=25010205;
RX   PubMed=25984343;
RX   PubMed=26351324;
RX   PubMed=26428435;
RX   PubMed=26979953;
RX   PubMed=28196595;
RX   PubMed=29464090;
RX   PubMed=30879952;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   https://www.cccells.org/PDF_Files/Ewings/TC-32.pdf
WW   https://www.cccells.org/tables/Ewings.php
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: 24 hours (PubMed=24312454); 36 hours (PubMed=25984343).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=25010205).
CC   Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=8040301; PubMed=25010205).
CC   Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Tyr636fs; Zygosity=Unspecified (PubMed=25010205; DepMap=ACH-001205).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.13%; Native American=0.3%; East Asian, North=1.12%; East Asian, South=0%; South Asian=0.2%; European, North=67.6%; European, South=30.65% (PubMed=30894373).
CC   Derived from site: In situ; Bone, left ilium; UBERON=UBERON_0001273.
ST   Source(s): PubMed=24312454; PubMed=25010205; PubMed=30879952
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 10,12
ST   D16S539: 13,14
ST   D18S51: 11,19
ST   D19S433: 12,14
ST   D21S11: 27,28
ST   D2S1338: 17,19
ST   D3S1358: 15,16
ST   D5S818: 12,13
ST   D7S820: 8,11
ST   D8S1179: 12
ST   FGA: 23,24
ST   TH01: 6,9.3
ST   TPOX: 9,11
ST   vWA: 15,18
DI   NCIt; C3716; Primitive neuroectodermal tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   17Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 31
//
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RA   Israel M.A., Thiele C.J.;
RT   "Tumor cell lines of the peripheral nervous system.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994).
//
RX   DOI=10.5282/edoc.27750;
RA   Orth M.F.;
RT   "Systematic multi-omics profiling of Ewing sarcoma cell lines.";
RL   Thesis PhD (2021), Ludwig Maximilians University of Munich, Germany.
//
RX   PubMed=3004699; DOI=10.1016/0165-4608(86)90001-4;
RA   Whang-Peng J., Triche T.J., Knutsen T., Miser J.S., Kao-Shan S.-C.,
RA   Tsai S., Israel M.A.;
RT   "Cytogenetic characterization of selected small round cell tumors of
RT   childhood.";
RL   Cancer Genet. Cytogenet. 21:185-208(1986).
//
RX   PubMed=3390826;
RA   McKeon C., Thiele C.J., Ross R.A., Kwan M., Triche T.J., Miser J.S.,
RA   Israel M.A.;
RT   "Indistinguishable patterns of protooncogene expression in two
RT   distinct but closely related tumors: Ewing's sarcoma and
RT   neuroepithelioma.";
RL   Cancer Res. 48:4307-4311(1988).
//
RX   PubMed=8040301; DOI=10.1172/JCI117360;
RA   Giovannini M., Biegel J.A., Serra M., Wang J.-Y., Wei Y.-L.H., Nycum L.,
RA   Emanuel B.S., Evans G.A.;
RT   "EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and
RT   primitive neuroectodermal tumors with variant translocations.";
RL   J. Clin. Invest. 94:489-496(1994).
//
RX   PubMed=16631476; DOI=10.1016/j.cancergencyto.2005.11.006;
RA   Szuhai K., IJszenga M., Tanke H.J., Rosenberg C., Hogendoorn P.C.W.;
RT   "Molecular cytogenetic characterization of four previously established
RT   and two newly established Ewing sarcoma cell lines.";
RL   Cancer Genet. Cytogenet. 166:173-179(2006).
//
RX   PubMed=22142829; DOI=10.1158/1078-0432.CCR-11-2056;
RA   Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.-Y., Marchetti A.,
RA   Borsu L., Barr F.G., Ladanyi M.;
RT   "Oncogene mutation profiling of pediatric solid tumors reveals
RT   significant subsets of embryonal rhabdomyosarcoma and neuroblastoma
RT   with mutated genes in growth signaling pathways.";
RL   Clin. Cancer Res. 18:748-757(2012).
//
RX   PubMed=24312454; DOI=10.1371/journal.pone.0080060;
RA   May W.A., Grigoryan R.S., Keshelava N., Cabral D.J., Christensen L.L.,
RA   Jenabi J., Ji L.-Y., Triche T.J., Lawlor E.R., Reynolds C.P.;
RT   "Characterization and drug resistance patterns of Ewing's sarcoma
RT   family tumor cell lines.";
RL   PLoS ONE 8:E80060-E80060(2013).
//
RX   PubMed=25010205; DOI=10.1371/journal.pgen.1004475;
RA   Brohl A.S., Solomon D.A., Chang W., Wang J.-J., Song Y., Sindiri S.,
RA   Patidar R., Hurd L., Chen L., Shern J.F., Liao H.-L., Wen X.-Y.,
RA   Gerard J., Kim J.-S., Lopez Guerrero J.A., Machado I., Wai D.H.,
RA   Picci P., Triche T.J., Horvai A.E., Miettinen M.M., Wei J.S.,
RA   Catchpoole D., Llombart-Bosch A., Waldman T., Khan J.;
RT   "The genomic landscape of the Ewing sarcoma family of tumors reveals
RT   recurrent STAG2 mutation.";
RL   PLoS Genet. 10:E1004475-E1004475(2014).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=26428435; DOI=10.1016/j.ejca.2015.08.020;
RA   Sand L.G.L., Scotlandi K., Berghuis D., Snaar-Jagalska B.E., Picci P.,
RA   Schmidt T., Szuhai K., Hogendoorn P.C.W.;
RT   "CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate
RT   with survival and metastases in Ewing sarcoma patients.";
RL   Eur. J. Cancer 51:2624-2633(2015).
//
RX   PubMed=26979953; DOI=10.1073/pnas.1521251113;
RA   Town J., Pais H., Harrison S., Stead L.F., Bataille C., Bunjobpol W.,
RA   Zhang J., Rabbitts T.H.;
RT   "Exploring the surfaceome of Ewing sarcoma identifies a new and unique
RT   therapeutic target.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:3603-3608(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29464090; DOI=10.18632/oncotarget.23815;
RA   Spurny C., Kailayangiri S., Altvater B., Jamitzky S., Hartmann W.,
RA   Wardelmann E., Ranft A., Dirksen U., Amler S., Hardes J., Fluegge M.,
RA   Meltzer J., Farwick N., Greune L., Rossig C.;
RT   "T cell infiltration into Ewing sarcomas is associated with local
RT   expression of immune-inhibitory HLA-G.";
RL   Oncotarget 9:6536-6549(2018).
//
RX   PubMed=30879952; DOI=10.1016/j.ymthe.2019.02.014;
RA   Kailayangiri S., Altvater B., Lesch S., Balbach S.T., Gottlich C.,
RA   Kuhnemundt J., Mikesch J.-H., Schelhaas S., Jamitzky S., Meltzer J.,
RA   Farwick N., Greune L., Fluegge M., Kerl K., Lode H.N., Siebert N.,
RA   Muller I., Walles H., Hartmann W., Rossig C.;
RT   "EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for
RT   targeting with gene-modified T cells.";
RL   Mol. Ther. 27:933-946(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//